
thumb|Stanley Erck (right) and Gregory Glenn (left) at the biotech labs in Gaithersburg during the visit of the Governor of [[Maryland in September 2020]] thumb|Novavax research and development laboratories in Gaithersburg Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.
via Wikipedia infobox
thumb|Stanley Erck (right) and Gregory Glenn (left) at the biotech labs in Gaithersburg during the visit of the Governor of [[Maryland in September 2020]] thumb|Novavax research and development laboratories in Gaithersburg Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).